Instil Bio
NASDAQ: TILUnicorn · $2.2BDallas, US · Founded 2018 · New York corporation · 51 employees on LinkedIn · 4 known investors
Find your way into Instil Bio
2 people in our graph share verified history with the Instil Bio team — schools, employers, funds. One of them is your warm intro.
Sumita Rayunlockedknows Bronson Crouch · together at Instil Bio (overlapped)
knows the team · via Curative Ventures
Instil Bio is a biotechnology company that identifies and acquires or licenses therapeutic candidates for development, with a strategic focus on securing additional novel drug candidates targeting diseases with significant unmet medical needs. The company previously pursued cell therapies including a folate receptor alpha-targeted tumor infiltrating lymphocyte therapy before discontinuing its former lead bispecific antibody program in early 2026.
Founders & leadership
Instil Bio was founded in 2018 by Bronson Crouch.
BC
Bronson CrouchinFounder · Chairman & CEOBronson Crouch is CEO and Chairman of Instil Bio, a biotechnology company identifying and developing therapeutic opportunities. He brings experience in life science and healthcare ventures across U.S. and international markets.
S"
Sandeep "Steve" LaumasinChief Financial Officer & Chief Business Officer
NS
GB
Gwen BinderNamed on SEC filing
NG
Neil GibsonNamed on SEC filing
GM
George MatchamNamed on SEC filing
Board
JN
KM
Kent McGaughyBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$381.2M disclosed across 4 rounds · 2019–2020
▶$185.4MraisedFeb 2021 · 26 investors · BiotechnologyRule 506(b)
▶$185.4MraisedFeb 2021 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sandeep LaumasExecutive Officer
- Gwen BinderDirector
- Nimish ShahDirector
- Jack NielsenDirector
- Neil GibsonDirector
- Kent McGaughyDirector
- Bronson CrouchExecutive Officer, Director
- George MatchamDirector
- Offering amount
- $185.4M
- Amount sold
- $185.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25MraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nimish ShahDirector
- Bronson CrouchExecutive Officer, Director
- Jack NielsenDirector
- Gwen BinderDirector
- Kent McGaughyDirector
- Neil GibsonDirector
- George MatchamDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$515.9KraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$515.9KraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- George MatchamDirector
- Gwen BinderDirector
- Jack NielsenDirector
- Bronson CrouchExecutive Officer, Director
- Neil GibsonDirector
- Nimish ShahDirector
- Kent McGaughyDirector
- Offering amount
- $515.9K
- Amount sold
- $515.9K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$170.2MraisedAug 2020 · 15 investors · BiotechnologyRule 506(b)
▶$170.2MraisedAug 2020 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nimish ShahDirector
- Jack NielsenDirector
- Kent McGaughyDirector
- Neil GibsonDirector
- Gwen BinderDirector
- Bronson CrouchExecutive Officer, Director
- George MatchamDirector
- Offering amount
- $170.2M
- Amount sold
- $170.2M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$2.2Bvaluation at IPOMar 2021 · $20.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Fortis Life Sciences13 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
StockTwits13 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TipRanks12 shared keywordsFinancial analysis and stock research platform.
Robinhood11 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Instil Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Instil Bio do?
- Instil Bio is a biotechnology company that identifies and acquires or licenses therapeutic candidates for development, with a strategic focus on securing additional novel drug candidates targeting diseases with significant unmet medical needs. The company previously pursued cell therapies including a folate receptor alpha-targeted tumor infiltrating lymphocyte therapy before discontinuing its former lead bispecific antibody program in early 2026.
- Who founded Instil Bio?
- Instil Bio was founded by Bronson Crouch in 2018.
- Who are Instil Bio's investors?
- Instil Bio's investors include Curative Ventures, Vivo Capital, CPMG, Venrock.
- How much funding has Instil Bio raised?
- Instil Bio has disclosed $381.2M raised across 4 rounds.
- Where is Instil Bio headquartered?
- Instil Bio is headquartered in Dallas, US.